Blurbs

B.Riley Financial Reaffirms Their Buy Rating on Altimmune (ALT)

In a report released today, Mayank Mamtani from B.Riley Financial reiterated a Buy rating on Altimmune (ALTResearch Report), with a price target of $26.00. The company’s shares closed yesterday at $11.65.

Mamtani covers the Healthcare sector, focusing on stocks such as Altimmune, Novavax, and Intercept Pharma. According to TipRanks, Mamtani has an average return of -30.7% and a 20.11% success rate on recommended stocks.

Currently, the analyst consensus on Altimmune is a Strong Buy with an average price target of $31.67, a 171.85% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $28.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $23.49 and a one-year low of $3.83. Currently, Altimmune has an average volume of 2.44M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Group is development stage company which intend to acquire an operating business, through a merger, capital stock exchange, asset acquisition or other similar business combination. The Group does not have any activities.

Read More on ALT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More